TY - JOUR
T1 - Ki-ras mutation and cell proliferation of lung lesions induced by 1- nitropyrene in A/J mice
AU - Bai, Feng
AU - Nakanishi, Yoichi
AU - Takayama, Koichi
AU - Pei, Xin Hai
AU - Tokiwa, Hiroshi
AU - Hara, Nobuyuki
PY - 1998/8/1
Y1 - 1998/8/1
N2 - In this study, lung lesions were found in male A/J mice 24 wk after intraperitoneal injection of 1-nitropyrene (1-NP). The lesions were classified into three categories: alveolar/bronchiolar hyperplasia, adenoma, and adenocarcinoma. The proliferation kinetics of cells in the lesions were evaluated by assessing proliferating cell nuclear antigen (PCNA) expression and silver-staining nucleolar organizer regions (AgNORs). Furthermore, the role of the Ki-ras gene in tumorigenesis was studied by detecting point mutations in Ki-ras codons 12, 13, and 61 by polymerase chain reaction and sequence analysis. The PCNA-positive rates (± standard deviations) in various samples were as follows: 0% for specimens from six untreated animals and six uninvolved areas, 4.26 ± 3.94% for 19 hyperplasias (hyperplasias vs normal lung tissue, P < 0.01), 13.24 ± 6.35% for 25 adenomas (adenomas vs hyperplasias, P < 0.01), and 38.0 ± 9.63% for four adenocarcinomas (adenocarcinomas vs adenomas, P < 0.01). The corresponding mean AgNOR scores were as follows: 1.10 ± 0.05 for the untreated animals, 1.32 ± 0.09 for the uninvolved areas, 1.72 ± 0.59 for the hyperplasias (hyperplasias vs normal lung tissue, P > 0.05), 2.74 ± 0.70 for the adenomas (adenomas vs hyperplasias, P < 0.01), and 5.22 ± 0.62 for the adenocarcinomas (adenocarcinomas vs adenomas, P < 0.01). Ki-ras gene mutations were identified in three of four (75%) adenocarcinomas, six of 23 (26%) adenomas, and two of 17 (12%) hyperplasias. No mutations were found in normal lung tissue. The most frequent Ki-ras mutation was an arginine (CGA) AT → GC transition at codon 61 in exon 2. The PCNA-positive rates and AgNOR scores of cases with Ki-ras mutations were higher than those without an identified mutation (P < 0.05). Ki-ras mutations at codon 61 (Arg) may therefore influence the growth or development of 1-NP-induced lung lesions in A/J mice.
AB - In this study, lung lesions were found in male A/J mice 24 wk after intraperitoneal injection of 1-nitropyrene (1-NP). The lesions were classified into three categories: alveolar/bronchiolar hyperplasia, adenoma, and adenocarcinoma. The proliferation kinetics of cells in the lesions were evaluated by assessing proliferating cell nuclear antigen (PCNA) expression and silver-staining nucleolar organizer regions (AgNORs). Furthermore, the role of the Ki-ras gene in tumorigenesis was studied by detecting point mutations in Ki-ras codons 12, 13, and 61 by polymerase chain reaction and sequence analysis. The PCNA-positive rates (± standard deviations) in various samples were as follows: 0% for specimens from six untreated animals and six uninvolved areas, 4.26 ± 3.94% for 19 hyperplasias (hyperplasias vs normal lung tissue, P < 0.01), 13.24 ± 6.35% for 25 adenomas (adenomas vs hyperplasias, P < 0.01), and 38.0 ± 9.63% for four adenocarcinomas (adenocarcinomas vs adenomas, P < 0.01). The corresponding mean AgNOR scores were as follows: 1.10 ± 0.05 for the untreated animals, 1.32 ± 0.09 for the uninvolved areas, 1.72 ± 0.59 for the hyperplasias (hyperplasias vs normal lung tissue, P > 0.05), 2.74 ± 0.70 for the adenomas (adenomas vs hyperplasias, P < 0.01), and 5.22 ± 0.62 for the adenocarcinomas (adenocarcinomas vs adenomas, P < 0.01). Ki-ras gene mutations were identified in three of four (75%) adenocarcinomas, six of 23 (26%) adenomas, and two of 17 (12%) hyperplasias. No mutations were found in normal lung tissue. The most frequent Ki-ras mutation was an arginine (CGA) AT → GC transition at codon 61 in exon 2. The PCNA-positive rates and AgNOR scores of cases with Ki-ras mutations were higher than those without an identified mutation (P < 0.05). Ki-ras mutations at codon 61 (Arg) may therefore influence the growth or development of 1-NP-induced lung lesions in A/J mice.
UR - http://www.scopus.com/inward/record.url?scp=0031857816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031857816&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1098-2744(199808)22:4<258::AID-MC7>3.0.CO;2-F
DO - 10.1002/(SICI)1098-2744(199808)22:4<258::AID-MC7>3.0.CO;2-F
M3 - Article
C2 - 9726818
AN - SCOPUS:0031857816
SN - 0899-1987
VL - 22
SP - 258
EP - 264
JO - Molecular Carcinogenesis
JF - Molecular Carcinogenesis
IS - 4
ER -